問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Rheumatology

CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of General Internal Medicine

Division of Rheumatology

更新時間:2023-09-19

蕭凱鴻
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

9Cases

2022-10-13 - 2027-04-20

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-11-01 - 2029-12-11

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2019-09-01 - 2024-05-14

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting8Sites

2024-09-01 - 2030-10-28

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2010-11-05 - 2011-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2022-11-01 - 2025-04-14

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting8Sites

2020-02-27 - 2024-01-31

Phase III

A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    (1) Filgotinib; (2) Adalimumab

Participate Sites
13Sites

Terminated13Sites

2018-06-29 - 2022-06-30

Phase II

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus
  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    BMS-986165

Participate Sites
8Sites

Recruiting8Sites

2010-03-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites